Andrew McConaghie
Senior Writer
Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
Apellis To Try Again After EMA Rejects Geographic Atrophy Drug
The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.
Moderna And GSK Hit By Declining RSV Vaccines Expectations
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.
Scholar Rock And Biohaven Get Ready To Flex Their Muscles In SMA
The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.
AstraZeneca’s Imfinzi Scores Hit In Bladder Cancer But Misses In NSCLC
The success in the NIAGRA bladder cancer study is welcome, but another failure in NSCLC means AstraZeneca has more riding on the AEGEAN study, with an FDA advisory board to review the lung cancer data due shortly.
Lilly In No Hurry To Share Results From Muscle-Building And Obesity Combination
A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.
Vertex Expands Trial As Type 1 Diabetes Cell Therapy Hits New Milestones
VX-880 is the first iteration of a cell therapy strategy which Vertex believes can bring curative treatment for Type 1 diabetes, but competition in this field is building.